Deigma acquired by Dedalus

Dedalus Healthcare France acquired the assets of Deigma on 3 November 2026 from founder Elisa Grimoin, who joined the acquirer as business developer for in vitro diagnostics in France. Founded in 2019 and based at the Plug N’work incubator at Colombelles in Normandy, Deigma operates a digital platform connecting medical testing laboratories with the self-employed nurses who collect samples at patients’ homes. The nurse records the prescription, the patient’s insurance details and the sample itself through the application, which transmits them directly to the laboratory’s information system. The company consisted of its founder alone, a neurobiology doctor who built the platform with the nurses who use it. Sample collection outside the laboratory accounts for more than 30% of a French laboratory’s activity and has attracted less investment than the analysis itself, which has been automated over successive generations of equipment. The information accompanying a home collection still travels on paper, is re-keyed on arrival and produces errors that invalidate samples or delay results. Laboratory consolidation has made that cost visible, since groups operating dozens of sites measure the administrative time absorbed by re-entry and the proportion of samples rejected, which is what gives a platform addressing it a measurable return. The two companies had been integrating their systems since 2023, before the acquisition formalised the relationship, and the acquirer intended to extend the platform’s functions and its place within the wider range of laboratory software it supplies.